Literature DB >> 17661529

Renal transplantation in high-risk patients.

Nicole A Weimert1, Rita R Alloway.   

Abstract

Renal transplantation in high-risk patients is a growing phenomenon. More patients are progressing to endstage renal failure, in the setting of an increased incidence of diabetes mellitus and cardiovascular disease. Current organ shortages and the use of more marginal donors have affected both patient and graft survival. Acute rejection has been minimised under modern immunosuppression; however, patient and long-term allograft outcomes have not improved concurrently. Specific understanding of donor, recipient and allograft variables associated with stratification of patients as 'high risk for renal transplantation' is necessary to facilitate appropriate peri- and post-transplant pharmacotherapy. Induction and maintenance immunosuppression choices are different for high-risk patients and must be made to ensure optimal immunosuppression, while limiting patient and allograft toxicity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17661529     DOI: 10.2165/00003495-200767110-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  124 in total

1.  Use of A(2) kidneys for B and O kidney transplant recipients: report of a series of patients transplanted at a single center spanning a decade.

Authors:  D J Norman; J C Prather; A M Alkhunaizi; A M deMattos; M Golconda; J M Barry
Journal:  Transplant Proc       Date:  2001 Nov-Dec       Impact factor: 1.066

2.  A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients.

Authors:  D C Brennan; K Flavin; J A Lowell; T K Howard; S Shenoy; S Burgess; S Dolan; J M Kano; M Mahon; M A Schnitzler; R Woodward; W Irish; G G Singer
Journal:  Transplantation       Date:  1999-04-15       Impact factor: 4.939

3.  Influence of polyclonal anti-thymocyte globulins upon ischemia-reperfusion injury in a non-human primate model.

Authors:  Andres Beiras-Fernandez; Daniel Chappell; Claus Hammer; Eckart Thein
Journal:  Transpl Immunol       Date:  2006-03-24       Impact factor: 1.708

4.  Corticosteroids in IgA nephropathy: a randomised controlled trial.

Authors:  C Pozzi; P G Bolasco; G B Fogazzi; S Andrulli; P Altieri; C Ponticelli; F Locatelli
Journal:  Lancet       Date:  1999-03-13       Impact factor: 79.321

5.  Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics.

Authors:  M Crespo; M Pascual; N Tolkoff-Rubin; S Mauiyyedi; A B Collins; D Fitzpatrick; M L Farrell; W W Williams; F L Delmonico; A B Cosimi; R B Colvin; S L Saidman
Journal:  Transplantation       Date:  2001-03-15       Impact factor: 4.939

6.  Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates.

Authors:  Akinlolu O Ojo; Julie A Hanson; Herwig-Ulf Meier-Kriesche; Chike N Okechukwu; Robert A Wolfe; Alan B Leichtman; Lawrence Y Agodoa; Bruce Kaplan; Friedrich K Port
Journal:  J Am Soc Nephrol       Date:  2001-03       Impact factor: 10.121

7.  Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.

Authors:  R A Montgomery; A A Zachary; L C Racusen; M S Leffell; K E King; J Burdick; W R Maley; L E Ratner
Journal:  Transplantation       Date:  2000-09-27       Impact factor: 4.939

8.  Risk factors for chronic rejection in renal allograft recipients.

Authors:  P S Almond; A Matas; K Gillingham; D L Dunn; W D Payne; P Gores; R Gruessner; J S Najarian
Journal:  Transplantation       Date:  1993-04       Impact factor: 4.939

9.  The pharmacokinetics and immunosuppressive response of tacrolimus in paediatric renal transplant recipients.

Authors:  Giovanni Montini; Francesca Ujka; Cristina Varagnolo; Luciana Ghio; Fabrizio Ginevri; Luisa Murer; Basile S Thafam; Carla Carasi; Graziella Zacchello; Mario Plebani
Journal:  Pediatr Nephrol       Date:  2006-03-21       Impact factor: 3.714

10.  The impact of HLA mismatches on the survival of first cadaveric kidney transplants.

Authors:  P J Held; B D Kahan; L G Hunsicker; D Liska; R A Wolfe; F K Port; D S Gaylin; J R Garcia; L Y Agodoa; H Krakauer
Journal:  N Engl J Med       Date:  1994-09-22       Impact factor: 91.245

View more
  3 in total

Review 1.  Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology.

Authors:  A Osama Gaber; Anthony P Monaco; James A Russell; Yvon Lebranchu; Mohamad Mohty
Journal:  Drugs       Date:  2010-04-16       Impact factor: 9.546

Review 2.  Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection.

Authors:  Emma D Deeks; Gillian M Keating
Journal:  Drugs       Date:  2009-07-30       Impact factor: 9.546

3.  Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study.

Authors:  A Durrbach; J M Pestana; S Florman; M Del Carmen Rial; L Rostaing; D Kuypers; A Matas; T Wekerle; M Polinsky; H U Meier-Kriesche; S Munier; J M Grinyó
Journal:  Am J Transplant       Date:  2016-06-09       Impact factor: 8.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.